AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 200 mg
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 400 mg
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 1600 mg
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 50 mg (elderly)
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 100 mg (elderly)
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 50 to 400 mg
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 882C87 with food
Number of subjects: 2
Study 7695306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5PU (metabolite)
Number of subjects: 2
Study 1978491 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 18
Study 1978491 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 18
Study 351218 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (adjusted dosage to achieve normoglycemia)
Number of subjects: 0
Study 351218 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0
Study 351218 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of insulin
Number of subjects: 0
Study 7039378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin (one 6 g dose at the start of the operation)
Number of subjects: 190
Study 7039378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin (three 2 g doses given at 4 hour intervals from the start of the operation)
Number of subjects: 190
Study 7039378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 28436545 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=35)
Number of subjects: 70
Study 28436545 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n=35)
Number of subjects: 70
Study 26446118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 263
Study 26446118 — intervention group
Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 263
Study 25006819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil (LY2140023 monohydrate)
Number of subjects: 103
Study 25006819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 22664806 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice multidetector computed tomography (MDCT)
Number of subjects: 0
Study 22664806 — intervention group
Group type: COMPARATOR
Intervention: Invasive coronary angiography
Number of subjects: 0
Study 20356721 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental reports of fatty acid deficiency symptoms (FADS)
Number of subjects: 450
Study 18372395 — intervention group
Group type: EXPERIMENTAL
Intervention: Solabegron 50 mg twice daily
Number of subjects: 36
Study 18372395 — intervention group
Group type: EXPERIMENTAL
Intervention: Solabegron 200 mg twice daily
Number of subjects: 36
Study 18372395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15703932 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc‐sestamibi in euthyroid volunteers (EVs)
Number of subjects: 90
Study 15703932 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in Graves' disease (GD) patients
Number of subjects: 90
Study 15703932 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in hypertrophic Hashimoto's thyroiditis (HHT) patients
Number of subjects: 90
Study 15703932 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in atrophic Hashimoto's thyroiditis (AHT) patients
Number of subjects: 90
Study 12875702 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone once daily plus sulphonylurea
Number of subjects: 198
Study 12875702 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g metformin twice daily plus sulphonylurea
Number of subjects: 198
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.05 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (all doses)
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg and 0.2 mg
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin and Simvastatin
Number of subjects: 0
Study 10563066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 0
Study 8887768 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate (HL)
Number of subjects: 7
Study 8887768 — intervention group
Group type: COMPARATOR
Intervention: Moderate lactate (C)
Number of subjects: 7
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk cereal fortified with ferrous fumarate (7.5 mg/100 g)
Number of subjects: 130
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk cereal fortified with ferric-pyrophosphate (7.5 mg/100 g)
Number of subjects: 130
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk cereal without iron fortification
Number of subjects: 130
Study 1957618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 130
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified cereals (both types)
Number of subjects: 130
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: All supplemented groups
Number of subjects: 130
Study 1957618 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 130
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin plus cloxacillin (2 g of each daily for 6 days)
Number of subjects: 429
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin (5 g X 12, 8‐hourly)
Number of subjects: 429
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: carbenicillin (10 g X 12, 8‐hourly)
Number of subjects: 429
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: short carbenicillin prophylaxis (1 day)
Number of subjects: 429
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin (900 mg, 4 daily doses)
Number of subjects: 429
Study 6359383 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin plus netilmicin (90 mg, 4 daily doses)
Number of subjects: 429
Study 6359383 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study 31206956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL/kg 24% sucrose
Number of subjects: 129
Study 31206956 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL/kg 24% sucrose
Number of subjects: 129
Study 29230663 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 µg/kg
Number of subjects: 569
Study 29230663 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 6 mg
Number of subjects: 569
Study 29230663 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 µg/kg and 6 mg
Number of subjects: 569
Study 29230663 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 569
Study 27222508 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 27222508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 25234339 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d of RRR‐α‐tocopherol
Number of subjects: 127
Study 25234339 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d of mixed tocopherols
Number of subjects: 127
Study 25234339 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/d of vitamin C
Number of subjects: 127
Study 25234339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d of grape‐seed polyphenols
Number of subjects: 127
Study 25234339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and polyphenols
Number of subjects: 127
Study 25234339 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neither vitamin C nor polyphenols)
Number of subjects: 127
Study 22391079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 μg, daily for 1 year
Number of subjects: 96
Study 22391079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 μg, daily for 1 year
Number of subjects: 96
Study 19685292 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 64
Study 19685292 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RCT)
Number of subjects: 64
Study 19685292 — intervention group
Group type: COMPARATOR
Intervention: Both RT and RCT
Number of subjects: 64
Study 18629723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quest plus NRT
Number of subjects: 346
Study 18629723 — intervention group
Group type: COMPARATOR
Intervention: Active control plus NRT
Number of subjects: 346
Study 18629723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quest plus placebo patch
Number of subjects: 346
Study 15773861 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume exercise group (HEG, n=20, 8.4 h week(‐1))
Number of subjects: 41
Study 15773861 — intervention group
Group type: COMPARATOR
Intervention: Medium-volume exercise group (MEG, n=21, 6 h week(‐1))
Number of subjects: 41
Study 11807358 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm membrane (hyaluronic acid-carboxymethylcellulose)
Number of subjects: 71
Study 11807358 — intervention group
Group type: COMPARATOR
Intervention: Control (no Seprafilm membrane)
Number of subjects: 71
Study 10450295 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH dietary patterns
Number of subjects: 0
Study 10450295 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu design and food production methodologies
Number of subjects: 0
Study 10450295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient database and menu evaluation
Number of subjects: 0
Study 10450295 — intervention group
Group type: EXPERIMENTAL
Intervention: Final menu adjustments
Number of subjects: 0
Study 8914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% or 0.5%) with epinephrine
Number of subjects: 100
Study 8914905 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1% or 2%) with epinephrine
Number of subjects: 100
Study 8914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 100
Study 8914905 — intervention group
Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 100
Study 1931628 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and misonidazole (PLUS MISO)
Number of subjects: 58
Study 1931628 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (NO MISO)
Number of subjects: 58
Study 6166691 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alone
Number of subjects: 32
Study 6166691 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside alone
Number of subjects: 32
Study 6166691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interferon and adenine arabinoside
Number of subjects: 32
Study 6166691 — intervention group
Group type: COMPARATOR
Intervention: No treatment (spontaneous decrease)
Number of subjects: 32
Study 30591073 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 100
Study 30591073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27753145 — intervention group
Group type: EXPERIMENTAL
Intervention: WSE + TENS
Number of subjects: 60
Study 27753145 — intervention group
Group type: COMPARATOR
Intervention: WSE + placebo TENS
Number of subjects: 60
Study 27753145 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 25543426 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate injection at auricular points (0.25 mL at each point)
Number of subjects: 90
Study 25543426 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fentanyl citrate injection in the deltoid muscle (1 mL)
Number of subjects: 90
Study 25543426 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous sodium chloride injection in the deltoid muscle (1 mL)
Number of subjects: 90
Study 22351892 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 group (500‐mg daily fish oil supplement and canola-based margarines and cooking oil)
Number of subjects: 616
Study 22351892 — intervention group
Group type: COMPARATOR
Intervention: Control group (500‐mg daily sunflower oil supplement and ω‐6 fatty acid-rich margarines and cooking oil)
Number of subjects: 616
Study 20691764 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with the left hand followed by nocturnal sleep (training at 8 pm and retrieval test at 8 am)
Number of subjects: 0
Study 20691764 — intervention group
Group type: COMPARATOR
Intervention: Training with the left hand followed by daytime wakefulness (training at 8 am and retrieval test at 8 pm)
Number of subjects: 0
Study 20691764 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with the left hand
Number of subjects: 0
Study 19000540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0
Study 19000540 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study 15940616 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 83
Study 15940616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 12837811 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC)
Number of subjects: 1218
Study 12837811 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL * min every 3 weeks (DCb)
Number of subjects: 1218
Study 12837811 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC)
Number of subjects: 1218
Study 10338227 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on test ordering standards
Number of subjects: 0
Study 8619702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia
Number of subjects: 399
Study 8619702 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic cross-clamping
Number of subjects: 399
Study 1751269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 1 ml kg‐1 with ketamine 0.5 mg kg‐1
Number of subjects: 50
Study 1751269 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 1 ml kg‐1
Number of subjects: 50
Study 1751269 — intervention group
Group type: COMPARATOR
Intervention: ketamine 0.5 mg kg‐1 with normal saline 1 ml kg‐1
Number of subjects: 50
Study 6762741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU)
Number of subjects: 30
Study 6762741 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) plus intradermic BCG
Number of subjects: 30
Study 31973599 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation package (experimental group)
Number of subjects: 20
Study 31973599 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 30859956 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day initiation regimen (ALNCD + 30mg oral aripiprazole)
Number of subjects: 0
Study 30859956 — intervention group
Group type: COMPARATOR
Intervention: 21-day oral aripiprazole regimen
Number of subjects: 0
Study 28109729 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium and mometasone furoate (MF) therapy
Number of subjects: 30
Study 28109729 — intervention group
Group type: COMPARATOR
Intervention: Montelukast only
Number of subjects: 30
Study 28109729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) only
Number of subjects: 30
Study 25772444 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) at doses of 0.4, 0.6, or 0.8 U/kg
Number of subjects: 33
Study 25772444 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (control)
Number of subjects: 33
Study 23122917 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS (2 mA, 25 min)
Number of subjects: 40
Study 23122917 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 40
Study 22059179 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-PR
Number of subjects: 409
Study 22059179 — intervention group
Group type: COMPARATOR
Intervention: Standard-PR
Number of subjects: 409
Study 19340550 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-sympathomimetic)
Number of subjects: 54
Study 19340550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19340550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive individuals
Number of subjects: 54
Study 19340550 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control persons
Number of subjects: 54
Study 16832639 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Number of subjects: 52
Study 16832639 — intervention group
Group type: COMPARATOR
Intervention: Tap water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Number of subjects: 52
Study 16832639 — intervention group
Group type: COMPARATOR
Intervention: Comparison of spa water therapy vs tap water therapy
Number of subjects: 52
Study 15539773 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex (interferon beta‐1a)
Number of subjects: 80
Study 15539773 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 80
Study 11328217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 245
Study 11328217 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 245
Study 9389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lutein
Number of subjects: 191
Study 9389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in plasma lutein
Number of subjects: 191
Study 9389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol
Number of subjects: 191
Study 9389900 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 191
Study 7642826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistuned fourth harmonic of a 90‐ms 12‐harmonic 155‐Hz fundamental complex tone preceded by four 90‐ms tones at the same frequency
Number of subjects: 0
Study 7642826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistuned component presented ipsilaterally
Number of subjects: 0
Study 7642826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistuned component presented contralaterally
Number of subjects: 0
Study 2746125 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut sutures
Number of subjects: 137
Study 2746125 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular studies of collagen proteins
Number of subjects: 137
Study 769147 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-release aspirin tablets given twice daily
Number of subjects: 36
Study 769147 — intervention group
Group type: COMPARATOR
Intervention: Aspirin B.P. tablets given four times daily
Number of subjects: 36
Study 769147 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-release aspirin tablets
Number of subjects: 36
Study 30707651 — intervention group
Group type: EXPERIMENTAL
Intervention: Telementoring support (TMS)
Number of subjects: 33
Study 26348699 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (GCBT)
Number of subjects: 88
Study 26348699 — intervention group
Group type: COMPARATOR
Intervention: Routine Psychosocial Rehabilitation (RPR) with access to Individual CBT (ICBT)
Number of subjects: 88
Study 23754735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg twice daily
Number of subjects: 378
Study 23754735 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg twice daily
Number of subjects: 378
Study 23754735 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg twice daily
Number of subjects: 378
Study 23754735 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 7.5 mg twice daily
Number of subjects: 378
Study 21788353 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + prednisone + custirsen (DPC)
Number of subjects: 42
Study 21788353 — intervention group
Group type: EXPERIMENTAL
Intervention: mitoxantrone + prednisone + custirsen (MPC)
Number of subjects: 42
Study 18420663 — intervention group
Group type: COMPARATOR
Intervention: Standardised usual care (control)
Number of subjects: 453
Study 18420663 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive self monitoring
Number of subjects: 453
Study 18420663 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive self monitoring
Number of subjects: 453
Study 17065671 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1129
Study 14499101 — intervention group
Group type: EXPERIMENTAL
Intervention: Family participation program in basic care for critically ill patients
Number of subjects: 117
Study 10856103 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-IV therapy (intensified therapy with a doubling of cyclophosphamide or ifosfamide equivalent dosing per cycle)
Number of subjects: 0
Study 10856103 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-IV therapy
Number of subjects: 0
Study 8635369 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam, 2 mg
Number of subjects: 0
Study 8635369 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam, 0.25 mg
Number of subjects: 0
Study 8635369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1734903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice chips
Number of subjects: 42